To exclude the possibility that the defective homing ability contributes to the effects of Fbxo22 loss, GFP+ AML cells sorted from Fbxo22+/+ and Fbxo22–/– recipients were injected into lethally irradiated mice, followed by detection of homed GFP+ AML cells in PB, spleen and BM. The gene discussed is FBXO22; the disease is acute myeloid leukemia.